tobramycin + dexamethasone + moxifloxacin

This is a combination ophthalmic drug containing **tobramycin**, **dexamethasone**, and **moxifloxacin**. Each component has a distinct role: - **Tobramycin** is an aminoglycoside antibiotic that binds the 30S subunit of bacterial ribosomes, blocking protein synthesis and leading to bacterial cell death. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid that suppresses inflammation by inhibiting multiple inflammatory cytokines and immune cell functions. - **Moxifloxacin** is a fourth-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes necessary for DNA replication, resulting in bactericidal activity. This combination would be aimed at treating or preventing bacterial eye infections with a significant inflammatory component, used in scenarios such as post-surgical prophylaxis or severe ocular infections. However, while double combinations like tobramycin+dexamethasone or moxifloxacin+dexamethasone are well established, a fixed triple combination of these three is rare or not widely marketed or approved in major countries based on current evidence.